Advances in Emerging Therapies 2007

Advances in emerging therapies 2007.

Cynics may consider that review of emergent stroke therapies in 2007 is likely to make for quick reading—it is certainly true that many high profile trials reported unexpected neutral outcomes. However, although these disappointments made for headline medical news, there were still a number of encouraging results of novel acute therapies. The first “casualty” of the year was neuroprotection. Th...

Advances in emerging nondrug therapies for acute stroke 2007.

Numerous clinical trials of thrombolytic and neuroprotective drugs for stroke have been conducted over the last 2 decades. The NINDS trial of intravenous tissue plasminogen activator remains the most notable success. Intra-arterial thrombolysis appears promising, but in the absence of phase III clinical trial data, this approach remains investigational. Numerous pharmaceutical drugs targeting 1...

Advances in Emerging Therapies 2006

The past year has seen further advancement toward the goal of effective and multifaceted stroke treatment. Encouraging evidence has emerged to support mechanical intervention for large artery occlusion, late and imagingdirected thrombolytic therapy, neuroprotectant strategies and decompressive surgery for large middle cerebral artery (MCA) stroke. We have seen important advances with regard to ...

Advances in stroke: emerging therapies.

O ver the past 2 years, the results of large clinical trials have fundamentally changed the clinical practice of stroke care in several different ways. Perhaps the greatest advances have occurred in stroke prevention, where we now have a wider array of anticoagulants to reduce the risk of stroke in patients with atrial fibrillation and we have confirmation from 2 large studies that medical ther...

Advances in emerging therapies 2009.